Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison.

Atkins, Michael B; Tarhini, Ahmad; Rael, Michael; Gupte-Singh, Komal; O'Brien, Elliott; Ritchings, Corey; Rao, Sumati; McDermott, David F

Atkins, Michael B; Tarhini, Ahmad; Rael, Michael; Gupte-Singh, Komal; O'Brien, Elliott; Ritchings, Corey; Rao, Sumati; McDermott, David F.

Affiliation

Atkins MB; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC 20057, USA.
Tarhini A; Center for Immuno-Oncology Research, Cleveland Clinic, Cleveland, OH 44106, USA.
Rael M; Evidera, Inc., San Francisco, CA 94111, USA.
Gupte-Singh K; Bristol-Myers Squibb, Princeton, NJ 08540, USA.
O'Brien E; Evidera, Inc., San Francisco, CA 94111, USA.
Ritchings C; Bristol-Myers Squibb, Princeton, NJ 08540, USA.
Rao S; Bristol-Myers Squibb, Princeton, NJ 08540, USA.
McDermott DF; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA.

Immunotherapy ; 11(7): 617-629, 2019 05.

Article in En | MEDLINE | ID: mdl-30852924

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Immunotherapy/methods; Melanoma/drug therapy; Molecular Targeted Therapy/methods; Adult; Azetidines/therapeutic use; Female; Follow-Up Studies; Humans; Imidazoles/therapeutic use; Ipilimumab/therapeutic use; Male; Melanoma/genetics; Melanoma/mortality; Middle Aged; Mutation/genetics; Neoplasm Staging; Nivolumab/therapeutic use; Oximes/therapeutic use; Piperidines/therapeutic use; Proto-Oncogene Proteins B-raf/antagonists & inhibitors; Proto-Oncogene Proteins B-raf/genetics; Pyridones/therapeutic use; Pyrimidinones/therapeutic use; Survival Analysis; Vemurafenib/therapeutic use

Key words

cobimetinib; comparative efficacy; dabrafenib; ipilimumab; matching-adjusted indirect comparison; nivolumab; trametinib; vemurafenib

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Molecular Targeted Therapy / Immunotherapy / Melanoma Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Immunotherapy Journal subject: ALERGIA E IMUNOLOGIA / TERAPEUTICA Year: 2019 Document type: Article Affiliation country: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google